- Novartis announced last week that European regulators have approved its follow-on biologic epoetin alfa, which is biosimilar to J&J's Eprex. Pharmalot posted this story today about J&J's reaction.
- The WSJ Health Blog had this interesting post last week reporting that more clinical trials are now under way in China than in India.
- Adams Respiratory Therapeutics is facing a patent challenge by Perrigo over its Mucinex cough medicine. Bloomberg recently published this report; MarketWatch.com had this one.
- The Wall St. Journal published this interesting article (subscription) a couple weeks ago about a drug development partnership between Eli Lilly and Chi-Med, a Chinese biotechnology company.
- FDA Law Blog had this post last month about impending FDA enforcement action on marketed unapproved drugs.
- Finally, a couple oldies but goodies from Pharma's Cutting Edge: Ariad v. Lilly patent litigation; response to Richard Epstein's Overdose.
OBB RSS Feed
Disclaimer
- Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended for other attorneys. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-2017
« ACI "Pharma/Biotech Patent Boot Camp" Conference, San Francisco, Sept. 18-19 | Main | Forest Labs' Lexapro Patent Withstands Teva's Appeal at Federal Circuit »
September 04, 2007
The comments to this entry are closed.
Search
Categories
- 180-Day Exclusivity (26)
- 271(e)(1) Safe Harbor (11)
- 271(e)(2) Jurisdiction (2)
- 30-Month Stay (2)
- Antitrust (49)
- Authorized Generics (20)
- Biosimilars (31)
- Citizen Petitions (22)
- Conferences (92)
- Declaratory Judgment Jurisdiction (25)
- FDA Announcements (7)
- FDA Litigation (12)
- Inequitable Conduct (4)
- Infringement--271(g) (1)
- Infringement--Direct (3)
- Infringement--Indirect (7)
- Inter Partes Review (5)
- Orange Book Issues (23)
- Paragraph IV Cases (204)
- Patent Eligibility (2)
- Patent Term Extension (11)
- Pediatric Exclusivity (14)
- Pharma Business News (38)
- Preliminary Injunction (2)
- Prosecution (1)
- Section viii Statements (5)
- Validity--Novelty (6)
- Validity--Obviousness (20)
- Validity--Section 101 (1)
- Validity--Section 112 (5)
Comments